Clinical trials · Massachusetts
Chronic Liver Disease clinical trials in Massachusetts
We’re tracking 21 recruiting chronic liver disease studies with a site in Massachusetts — including Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT05205954Recruiting
Home hospital care for adults with advanced liver disease
This pilot study tests whether a “home hospital” program can safely care for people with advanced liver disease after they are admitted to the hospital. It may reduce time in the hospital while still treating serious complications like fluid buildup, breathing fluid, or confusion from liver disease.
Boston, MassachusettsAges 18 years+ - NCT05998330Recruiting
Palliative care support for advanced liver disease patients
This study tests whether adding palliative care (extra support for symptoms and planning) during a hospital stay helps people with advanced liver disease and their caregivers feel better and plan ahead.
Boston, MassachusettsAges 18 years+ - NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT06592820Recruiting
Ultrasound stiffness test for fatty liver disease
This study uses a special ultrasound technique, called shear wave elastography, to measure liver stiffness during an endoscopic ultrasound (EUS) procedure. It aims to see how well this new method detects liver scarring (fibrosis) in people with fatty liver disease, compared to standard tests like FibroScan and liver biopsy.
Boston, MassachusettsAges 18 years+ - NCT07082738RecruitingPhase 2
Study of AZD6793 for people with moderate to very severe COPD
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
Burlington, MassachusettsAges 40 years+ - NCT05919680RecruitingPhase 2
NST-6179 for liver disease from intestinal failure in adults
This Phase 2 study tests NST-6179 in people who have intestinal failure–associated liver disease (IFALD). It aims to improve liver function and overall outcomes for people whose liver inflammation and lab tests have been abnormal for at least 6 months.
Boston, MassachusettsAges 16 years+ - NCT06907147Recruiting
Renal denervation for uncontrolled high blood pressure
This trial tests a procedure called renal denervation to lower blood pressure in people whose medication isn't enough. It uses a special catheter to calm nerves near the kidneys that may be overactive.
Boston, MassachusettsAges 18–80 - NCT04899102Recruiting
Intermittent fasting for fatty liver disease in adults
This study tests whether intermittent fasting can improve fatty liver disease (NAFLD) by reducing liver fat. It focuses on adults with confirmed fatty liver and extra liver fat seen on a special MRI scan.
Boston, MassachusettsAges 18 years+ - NCT07011810RecruitingPhase 2
Axatilimab for sclerotic chronic graft-versus-host disease
This study tests a new drug called axatilimab for people with a specific type of chronic graft-versus-host disease (cGVHD) that causes hardening or thickening of the skin or joints. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack your body. The study aims to see if axatilimab can improve these sclerotic symptoms. If you have this condition and it was recently diagnosed (within the last year), you might qualify to participate.
Boston, MassachusettsAges 18 years+ - NCT06585774RecruitingPhase 3
Axatilimab plus steroids for new chronic GVHD
This study tests a new drug called axatilimab combined with steroids as a first treatment for chronic graft-versus-host disease (GVHD) after a stem cell transplant. It aims to see if this combination helps control symptoms better than steroids alone.
Boston, MassachusettsAges 12 years+ - NCT06165341RecruitingPhase 3
Fazirsiran for mild liver scarring in alpha-1 antitrypsin deficiency
This study tests an investigational drug called fazirsiran, which is designed to treat alpha-1 antitrypsin deficiency-related liver disease with mild scarring. The goal is to see if fazirsiran is safe and can improve or slow liver damage in people with the PiZZ genetic type.
Boston, MassachusettsAges 18–75 - NCT06632600RecruitingPhase 2
Study of LXE408 for people with chronic Chagas disease
This trial tests a new drug called LXE408 for people with chronic Chagas disease. It aims to see if the drug is safe and effective, and participants will also receive standard treatment with benznidazole.
Boston, MassachusettsAges 18–60 - NCT06632444RecruitingPhase 3
Study of survodutide for liver disease NASH/MASH with fibrosis
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Boston, MassachusettsAges 18 years+ - NCT06274788Recruiting
Safety study of long-term Omegaven for liver problems from IV nutrition
This study checks if children who need Omegaven for eight weeks or longer develop a lack of essential fats. It is for kids with liver issues caused by IV nutrition who cannot eat or digest food normally.
Boston, MassachusettsAges 1 day–17 years - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Burlington, MassachusettsAges 18–80 - NCT04496479RecruitingPhase 2
Transplanting donor liver cells near lymph nodes in advanced liver disease
This Phase 2 study tests whether transplanting donor liver cells near lymph nodes can improve outcomes in people with advanced cirrhosis from certain liver conditions. It may help your liver function by adding healthy liver cells, but eligibility is tightly based on your current liver status and other health factors.
Boston, MassachusettsAges 18–70 - NCT05677971RecruitingPhase 3
Tested medicine to treat liver scarring in PiZZ alpha-1 disease
This Phase 3 study tests fazirsiran for safety and whether it can help people with a specific genetic form of alpha-1 antitrypsin–related liver disease that causes liver scarring. You may be eligible if you have the PiZZ genetic type and moderate-to-severe fibrosis, with certain lung and liver conditions ruled out.
Boston, MassachusettsAges 18–75 - NCT07728695RecruitingPhase 1/Phase 2
Cannabis product for gynecologic pain study
This trial tests a new cannabis-based product to see if it helps with gynecologic pain (like endometriosis). It looks at how the product works and whether it is safe and effective.
Belmont, MassachusettsAges 21 years+ - NCT06217302RecruitingPhase 3
Sotagliflozin for kidney protection in type 1 diabetes
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
Boston, MassachusettsAges 18–75 - NCT07024706RecruitingPhase 2
Study of acalabrutinib plus venetoclax for relapsed CLL
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
Boston, MassachusettsAges 18–130 - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Boston, MassachusettsAges 18–66
Chronic Liver Disease trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting chronic liver disease studies listed above.
- Boston Medical Center · 4 studies
- Massachusetts General Hospital · 4 studies
- Brigham and Women's Hospital · 3 studies
- Dana-Farber Cancer Institute · 3 studies
- Boston Children's Hospital · 2 studies
- Research Site · 2 studies
- 89bio Clinical Site
- Beth Israel Deaconess Medical Center
What taking part in a chronic liver disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there chronic liver disease clinical trials in Massachusetts?
- Yes. We're currently tracking 21 recruiting chronic liver disease studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a chronic liver disease study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a chronic liver disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New chronic liver disease studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.